135 related articles for article (PubMed ID: 26775891)
1. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
Seishima R; Okabayashi K; Nagano O; Hasegawa H; Tsuruta M; Shimoda M; Kameyama K; Saya H; Kitagawa Y
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):487-93. PubMed ID: 26775891
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cell markers CD44v9+/CD133- are associated with low apoptosis in both sporadic and ulcerative colitis-associated colorectal cancers.
Nakagomi E; Mikami T; Funahashi K; Okazumi S; Shibuya K; Hiruta N; Igarashi Y
Histol Histopathol; 2022 Jun; 37(6):587-595. PubMed ID: 35224715
[TBL] [Abstract][Full Text] [Related]
3. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
5. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
[TBL] [Abstract][Full Text] [Related]
6. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression.
Yasui W; Kudo Y; Naka K; Fujimoto J; Ue T; Yokozaki H; Tahara E
Int J Oncol; 1998 Jun; 12(6):1253-8. PubMed ID: 9592182
[TBL] [Abstract][Full Text] [Related]
8. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H
Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440
[TBL] [Abstract][Full Text] [Related]
9. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
van Schaik FD; Oldenburg B; Offerhaus GJ; Schipper ME; Vleggaar FP; Siersema PD; van Oijen MG; Ten Kate FJ
Inflamm Bowel Dis; 2012 Mar; 18(3):480-8. PubMed ID: 21509910
[TBL] [Abstract][Full Text] [Related]
10. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.
Akamine T; Tagawa T; Ijichi K; Toyokawa G; Takamori S; Hirai F; Okamoto T; Oda Y; Maehara Y
Ann Surg Oncol; 2019 May; 26(5):1544-1551. PubMed ID: 30798450
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation.
Suwannakul N; Ma N; Thanan R; Pinlaor S; Ungarreevittaya P; Midorikawa K; Hiraku Y; Oikawa S; Kawanishi S; Murata M
Mediators Inflamm; 2018; 2018():4867234. PubMed ID: 30402042
[TBL] [Abstract][Full Text] [Related]
12. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis.
Gan HT; Chen YQ; Ouyang Q
J Gastroenterol Hepatol; 2005 Jul; 20(7):1016-24. PubMed ID: 15955209
[TBL] [Abstract][Full Text] [Related]
13. CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.
Taniguchi D; Saeki H; Nakashima Y; Kudou K; Nakanishi R; Kubo N; Ando K; Oki E; Oda Y; Maehara Y
Cancer Med; 2018 Dec; 7(12):6258-6268. PubMed ID: 30474922
[TBL] [Abstract][Full Text] [Related]
14. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.
Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression.
Maruyama Y; Uehara T; Daikuhara S; Kobayashi Y; Nakajima T; Matsumoto A; Tanaka E; Ota H
Pathology; 2015 Dec; 47(7):647-52. PubMed ID: 26517627
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer.
Katoh S; Goi T; Naruse T; Ueda Y; Kurebayashi H; Nakazawa T; Kimura Y; Hirono Y; Yamaguchi A
Anticancer Res; 2015 Jan; 35(1):239-44. PubMed ID: 25550556
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment.
Lee HJ; Choi SC; Lee MH; Oh HM; Choi EY; Choi EJ; Yun KJ; Seo GS; Kim SW; Lee JG; Han WC; Park KI; Jun CD
Inflamm Bowel Dis; 2005 Dec; 11(12):1070-9. PubMed ID: 16306769
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
[TBL] [Abstract][Full Text] [Related]
20. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells.
Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S
Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
